Caplin Point Laboratories is a pharmaceutical company established in 1990 to provide external applications like ointments, creams, and more. With the help of 4 manufacturing sites in India and 3 R&D facilities, Caplin produces over 4000 products with more than 650 formulations in 36 different therapeutic areas. For products where in-house manufacturing is restricted, Caplin is part of an Outsourced Manufacturing initiative wherein it develops and transfers product technology to other approved sites. It is increasingly supplying its licensed active pharmaceutical ingredients (APIs), finished formulations, and generics, as well as clinical research, to Latin America, Africa, the USA, and the EU.
PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (INR Cr) | 1836 17.0% | 1570 17.1% | 1340 33.7% | 1002 -8.8% | 1100 62.2% | 678 22.2% | 555 34.9% | 411 69.3% | 243 -4.9% | 256 43.8% | 178 36.4% | 130 19.0% | 110 30.7% | 84 37.0% | 61 -4.7% | 64 -0.1% | 64 - |
Net Operating Income (INR Cr) | 1694 15.50% | 1467 15.54% | 1269 19.61% | 1061 22.95% | 863 33.07% | 649 20.16% | 540 34.41% | 402 68.25% | 239 -5.18% | 252 45.46% | 173 36.26% | 127 18.49% | 107 32.72% | 81 0.00% | 58 -1.81% | 59 -5.06% | 62 63.91% |
Profit (INR Cr) | 457 21.5% | 376 25.5% | 300 23.8% | 242 12.7% | 215 21.8% | 177 22.0% | 145 51.4% | 96 108.9% | 46 11.5% | 41 58.8% | 26 84.9% | 14 74.5% | 8 27.6% | 6 88.6% | 3 50.0% | 2 113.5% | 1 - |
Assets (INR Cr) | 2368 22.8% | 1928 26.0% | 1530 23.6% | 1237 22.7% | 1009 57.8% | 639 72.8% | 370 63.4% | 226 71.4% | 132 37.0% | 96 45.9% | 66 36.8% | 48 18.4% | 41 4.4% | 39 9.1% | 36 10.4% | 32 -0.5% | 33 - |
Net Worth (INR Cr) | 2099 26.2% | 1664 31.3% | 1267 30.8% | 969 11.0% | 873 46.3% | 597 64.1% | 364 61.9% | 225 80.7% | 124 39.1% | 89 44.9% | 62 56.7% | 39 32.1% | 30 17.7% | 25 0.0% | 22 7.9% | 20 12.4% | 18 28.0% |
Employee Cost (INR Cr) | 144 4.8% | 137 18.8% | 115 12.5% | 103 51.3% | 68 43.8% | 47 20.4% | 39 27.0% | 31 66.8% | 18 -1.7% | 19 47.2% | 13 63.4% | 8 23.0% | 6 53.4% | 4 56.8% | 3 -1.5% | 3 -21.6% | 3 - |
Interest Cost (INR Cr) | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Cash & Bank Balance (INR Cr) | 553 | 493 | 463 | 438 | 223 | 153 | 79 | 93 | 68 | 45 | 27 | 17 | 32 | 22 | 15 | 17 | 10 |
Total Debt (INR Cr) | 2 | 5 | 2 | 18 | 39 | 1 | 1 | 1 | 2 | 2 | 3 | 5 | 7 | 10 | 10 | 9 | 11 |
PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit As % Of Revenues | 24.9% | 24.0% | 22.4% | 24.2% | 19.6% | 26.1% | 26.1% | 23.2% | 18.8% | 16.1% | 14.5% | 10.7% | 7.3% | 7.5% | 5.4% | 3.5% | 1.6% |
Profit As % Of Assets | 19.3% | 19.5% | 19.6% | 19.6% | 21.3% | 27.6% | 39.2% | 42.3% | 34.7% | 42.6% | 39.1% | 28.9% | 19.6% | 16.1% | 9.3% | 6.9% | 3.2% |
Profit As % Of Networth | 21.8% | 22.6% | 23.7% | 25.0% | 24.6% | 29.6% | 39.8% | 42.5% | 36.8% | 45.9% | 41.9% | 35.5% | 26.8% | 24.8% | 15.3% | 11.0% | 5.8% |
Interest Cost to EBITDA % | 0.1% | 0.2% | 0.2% | 0.5% | 0.1% | 0.3% | 0.3% | 0.4% | 0.5% | 1.6% | 1.9% | 3.5% | 11.3% | 13.0% | 43.6% | 45.9% | 39.0% |
Debt to Equity Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.04 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.05 | 0.12 | 0.23 | 0.38 | 0.48 | 0.43 | 0.61 |
RONW | 24.5% | 25.7% | 27.6% | 27.3% | 29.3% | 36.8% | 49.2% | 54.7% | 57.1% | 54.4% | 51.3% | 40.5% | 29.1% | 21.5% | 15.9% | 11.7% | 5.2% |
ROCE | 26.7% | 26.6% | 28.4% | 28.4% | 32.9% | 45.1% | 63.5% | 68.6% | 73.1% | 68.7% | 65.9% | 56.2% | 34.4% | 23.5% | 15.3% | 15.2% | 8.1% |